Manufacturing

Oct 20, 2017
By BioPharm International Editors
The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.
Oct 18, 2017
By BioPharm International Editors
The partnership and the formation of the institute intend to bring together industry, academia, and regulators to tackle challenges and provide solutions for continuous manufacturing.
Oct 16, 2017
By BioPharm International Editors
The company announced plans to expand its viral vector process development facilities in the United States and its cleanroom facilities in the Netherlands for vector-based products.
Oct 12, 2017
By BioPharm International Editors
The companies have entered into a strategic collaboration to establish a new cell therapy and regenerative medicine manufacturing platform, which includes a new manufacturing facility in Belgium.
Oct 12, 2017
By BioPharm International Editors
The company is investing EUR 170 million (US$201 million) to expand its vaccine manufacturing site in France for its newest influenza vaccine.
Oct 11, 2017
By BioPharm International Editors
Johnson & Johnson’s Janssen Sciences Ireland UC will invest more than EUR 300 million (US$355 million) to expand manufacturing capacity for biologic medicines at its Ireland facility.
Oct 06, 2017
By BioPharm International Editors
Under an agreement, ProBioGen will develop a stable cell-line for and manufacture an anti-cancer antibody for Chiome using its proprietary cancer cell-killing technology.
Oct 01, 2017
BioPharm International
Process analytical testing for biopharmaceuticals requires enhanced methods due to complex bioprocesses.
Oct 01, 2017
BioPharm International
Manufacturers introduce innovations in glass and plastic packaging for injectables.
Sep 27, 2017
By BioPharm International Editors
Fresenius Kabi broke ground on a previously announced $250 million expansion of its Melrose Park, IL, manufacturing facility.
native1_300x100
lorem ipsum